Evolent Health Inc (NYSE:EVH) has been given a consensus rating of “Buy” by the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $32.30.
EVH has been the topic of several recent research reports. Citigroup raised their price target on shares of Evolent Health from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 4th. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Tuesday, December 4th. ValuEngine raised shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a report on Friday, September 14th. Cantor Fitzgerald reissued a “buy” rating and issued a $37.00 price target on shares of Evolent Health in a report on Monday, December 31st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $34.00 target price on shares of Evolent Health in a research report on Wednesday, November 7th.
A number of hedge funds have recently added to or reduced their stakes in EVH. Vanguard Group Inc increased its stake in Evolent Health by 8.3% in the 3rd quarter. Vanguard Group Inc now owns 5,713,530 shares of the technology company’s stock worth $162,264,000 after buying an additional 439,172 shares during the period. Rehmann Capital Advisory Group grew its position in shares of Evolent Health by 2,002.7% in the 3rd quarter. Rehmann Capital Advisory Group now owns 14,677 shares of the technology company’s stock worth $417,000 after buying an additional 13,979 shares during the last quarter. Vanguard Group Inc. boosted its stake in Evolent Health by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,713,530 shares of the technology company’s stock worth $162,264,000 after purchasing an additional 439,172 shares in the last quarter. Lombard Odier Asset Management USA Corp boosted its stake in Evolent Health by 724.0% in the 3rd quarter. Lombard Odier Asset Management USA Corp now owns 206,000 shares of the technology company’s stock worth $5,850,000 after purchasing an additional 181,000 shares in the last quarter. Finally, Standard Life Aberdeen plc boosted its stake in Evolent Health by 27.3% in the 3rd quarter. Standard Life Aberdeen plc now owns 1,871,543 shares of the technology company’s stock worth $53,105,000 after purchasing an additional 401,893 shares in the last quarter.
NYSE EVH opened at $18.26 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.50 and a quick ratio of 2.50. Evolent Health has a fifty-two week low of $13.06 and a fifty-two week high of $29.05. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -26.09 and a beta of 1.72.
Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Tuesday, November 6th. The technology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.07. The business had revenue of $150.16 million during the quarter, compared to the consensus estimate of $142.94 million. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. Evolent Health’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.18) earnings per share. As a group, analysts predict that Evolent Health will post -0.33 EPS for the current fiscal year.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
See Also: Capital gains and your 401(k) or IRA
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.